Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522

KEYNOTE-522: optimal preoperative IO and residual disease management in TNBCПодробнее

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBCПодробнее

KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBCПодробнее

Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBCПодробнее

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...Подробнее

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast CancerПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancerПодробнее

KEYNOTE-522: Neoadjuvant pembro + chemo vs placebo + chemo, followed by adjuvant pembro vs place...Подробнее

A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 studyПодробнее

Phase 3 KEYNOTE-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early TNBCПодробнее

Update on Keynote 522, the current standard of care for triple negative breast cancer.Подробнее

Dr. Rugo on the Results of the KEYNOTE-522 Trial in TNBCПодробнее

KEYNOTE-522: EFS sensitivity & subgroup analysesПодробнее

Early TNBC - Pembrolizumab + chemotherapy: Pathologic complete response in key subgroupsПодробнее

Neoadjuvant chemoimmunotherapy: KEYNOTE-522, I-SPY & moreПодробнее

The case for neoadjuvant pembrolizumab in TNBCПодробнее

KEYNOTE-522 studyПодробнее

Immunotherapy added to chemotherapy improves pathological complete response in early triple nega...Подробнее